We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bayer HealthCare Collaborates with Sysmex Inostics on Companion Diagnostics

By LabMedica International staff writers
Posted on 22 Oct 2013
Bayer HealthCare (Leverkusen, Germany) has entered into a collaboration agreement with the diagnostic company Sysmex Inostics GmbH (Hamburg, Germany) for the development of companion diagnostics for targeted cancer therapies. More...
The blood-based companion diagnostic solutions offered by Sysmex Inostics will complement anticancer agents developed by Bayer.

The companion diagnostic tests are used to discover which patients are more likely to respond to a particular anticancer agent. Under the agreement, Sysmex Inostics will develop blood-based diagnostic tests based on its BEAMing technology. These tests enable a very sensitive analysis of circulating tumor DNA shed into the blood stream from tumors. This provides a noninvasive alternative to tumor biopsy to analyze the mutational status of a patient’s tumor. The noninvasive diagnostic blood tests allow the selection of an appropriate therapeutic agent without the need of further surgeries or tumor biopsies. The blood-based diagnostic DNA tests can be performed on patients where no tumor tissue is available.

An initial blood-based companion diagnostic test will be applied in clinical trials to select patients more likely to achieve a clinical benefit to an investigational anticancer agent developed by Bayer HealthCare. The partnership also provides a framework for further collaboration projects to develop molecular blood-based diagnostic tests in support of additional targeted cancer therapies. Financial terms of the agreement were not disclosed.

Sysmex Inostics, a subsidiary of Sysmex Corporation, is a molecular diagnostic company whose core competency is mutation detection utilizing highly sensitive technologies such as Plasma-Sequencing and BEAMing. Sysmex Inostics companion diagnostics (CDx) team offers services for the development of non-invasive plasma DNA based in vitro diagnostic (IVD) tests supported by a network of partners to cover the entire IVD development process.

Bayer HealthCare, a subgroup of Bayer AG, is a global enterprise with core competencies in the fields of health care, agriculture, and high-tech materials. The company combines the global activities of the Animal Health, Consumer Care, Medical Care, and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture, and market products that will improve human and animal health worldwide.

Related Links:

Bayer HealthCare
Sysmex Inostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Platelet Function Analyzer
PL-12
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.